Appointment of Stacy Price as Chief Technology Officer strengthens Upstream Bio's leadership team with her extensive experience in technical operations and product development in the biotechnology ...

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial ...

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...

A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website ...

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Upstream Bio, Inc. with a $52.25 average price target, representing a 68.2% upside. In a report issued on January ...

– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in ...

Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions ...

Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has ...

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...